The S&P 500 ($SPX) just logged its fifth straight trading box breakout, which means that, of the five trading ranges the index has experienced since...
Lawmakers on the House Homeland Security Committee met with stakeholders and law enforcement to address the rise of antisemitic violence in the U.S., during...
From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major...
The Senate confirmed President Donald Trump’s pick to lead the Centers for Disease Control and Prevention after his first choice struggled to gain support....
The Senate confirmed President Donald Trump’s nominee Emil Bove as a federal judge Tuesday, handing a controversial leader at the Department of Justice a...
Investor Insight With high-quality, drill-ready assets with world-class discovery potential, Piche Resources is a compelling business case for investors looking to leverage a bull...
When Canadian-Russian programmer Vitalik Buterin penned a white paper in 2013 outlining a new kind of blockchain platform, few could have predicted the seismic...
The S&P 500 ($SPX) just logged its fifth straight trading box breakout, which means that, of the five trading ranges the index has experienced since...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
Colleen Hroncich Alexandra Batista was ready to quit teaching. Over the years, she had taught at various schools geared toward autistic children, but she...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets....
Colin Grabow On occasion, and increasingly of late, one encounters the argument that libertarians and other free trade/free market types suffer from a blindspot concerning...
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...